Literature DB >> 33835972

Pathological Features and Imaging Findings in Pancreatic Carcinoma In Situ.

Keiji Hanada1, Motomitsu Fukuhara2, Tomoyuki Minami3, Shigeki Yano2, Juri Ikemoto2, Akinori Shimizu1, Keisuke Kurihara1, Yasuhiro Okuda1, Morito Ikeda1, Masataka Yokode1, Tomoyuki Abe4, Shuji Yonehara5, Akio Yanagisawa6.   

Abstract

OBJECTIVES: This study aimed to evaluate the pathological features and imaging findings of pancreatic carcinoma in situ (PCIS).
METHODS: Twenty patients with PCIS were categorized as flat (F) (n = 6) and low papillary (LP) (n = 14) types.
RESULTS: None of F type and 8 (57%) of 14 with LP type lesions showed intraductal infiltrations of the main pancreatic duct (MPD) greater than 10 mm. None of F type and 3 (21%) of 14 with LP type lesions showed skip lesions in the MPD. Magnetic resonance cholangiopancreatography showed irregular MPD stenoses in 5 (83%) of 6 with F and 13 (100%) of 13 with LP type lesions. Magnetic resonance cholangiopancreatography determined that the median lengths of the irregular MPD stenoses were 3.6 mm for F, and 11.6 mm for LP type lesions. Endoscopic retrograde cholangiopancreatography determined that the median lengths of the irregular MPD stenoses were 2.8 mm for F, and 14.3 mm for LP type lesions. Pancreatic cancer recurrences limited to the remnant pancreas occurred in 2 patients with LP type lesions.
CONCLUSIONS: In LP type PCIS, intraductal infiltration of the MPD occurs frequently. There may be multiple lesions, and lesions may recur in the remnant pancreas. Long-term strict follow-up assessments should be implemented for LP type PCIS.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33835972     DOI: 10.1097/MPA.0000000000001771

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  1 in total

1.  The Clinical Diagnostic Value of F-FDG PET/CT Combined with MRI in Pancreatic Cancer.

Authors:  Xinyan Liu; Yi Ren; Jianying Wang; Xiujin Yang; Li Lu
Journal:  Contrast Media Mol Imaging       Date:  2022-08-04       Impact factor: 3.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.